Phase 2 Peripheral Arterial Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years at the time of signing consent
• People with a laboratory-confirmed blood cancer or related condition, including: B-cell acute lymphoblastic leukaemia (B-ALL); B-cell non-Hodgkin lymphoma, chronic lymphocytic leukaemia, or small lymphocytic lymphoma; multiple myeloma or plasma cell leukaemia; acute myeloid leukaemia, high-risk myelodysplastic syndrome, or a rare blood cancer called BPDCN; or T-cell acute lymphoblastic leukaemia, T-cell lymphoblastic lymphoma, or peripheral T-cell lymphoma
• People whose cancer has come back or stopped responding to treatment after at least 2 previous treatment courses, or where no standard curative or approved treatment is considered appropriate by the treating doctor
• People whose cancer cells are confirmed by a central laboratory to be suitable for the trial's treatment approach, based on specific proteins found on the cancer cells and a safety review
• People whose cancer can be measured or tracked using standard assessment methods for their specific disease
• People with a general health and activity level rated at 0, 1, or 2 on a standard medical scale (meaning fully active to capable of limited self-care)
• People whose heart, kidneys, liver, and lungs are functioning at or above the minimum levels required by the trial
• People with adequate blood cell counts, unless low counts are clearly caused by the cancer itself
• People who are physically able to undergo a blood cell collection procedure called leukapheresis and are willing to follow the trial schedule and attend follow-up visits
• People who have previously received a stem cell transplant from a donor, provided it was at least 100 days ago, there is no active uncontrolled graft-versus-host disease, and no significant immune-suppressing medications are being taken
• People of childbearing potential who have a negative pregnancy test before starting and agree to use effective contraception during periods defined by the trial
• People who have given written informed consent before any trial-related procedures begin

Who may not be able to join:

• People with an active, uncontrolled infection — including bacterial, fungal, or viral infections — or signs of serious blood infection (sepsis)
• People with active cancer spread to the brain or spinal cord that is currently requiring increasing treatment (previously treated and stable central nervous system disease may be considered — confirm with trial site)
• People who received a previous gene-modified cell therapy (such as another CAR-T treatment) within 12 weeks before the cell collection procedure, or who still have unresolved serious side effects (Grade 3 or higher) from a previous cancer treatment
• People whose cancer is advancing so rapidly that the time needed to manufacture the trial treatment would pose an unacceptable risk
• People with an active autoimmune disease that requires immune-suppressing medications, with limited exceptions for low-dose steroids or certain inhaled or topical treatments as permitted by the trial
• People who have previously received a solid organ transplant (such as a kidney, liver, or heart transplant)
• People with serious heart conditions, including uncontrolled irregular heartbeat, heart failure that is not compensated, a heart attack within the past 6 months, or a stroke within the past 6 months
• People with HIV, hepatitis B, or hepatitis C that is not under control
• People who are pregnant or breastfeeding
• People who have another active cancer currently requiring systemic treatment, with limited exceptions for certain low-risk, definitively treated cancers as defined by the trial (confirm with trial site)
• People with a known serious allergy or hypersensitivity to fludarabine, cyclophosphamide, or key ingredients in the trial product
• People for whom a suitable CAR-T cell product cannot be successfully manufactured or does not meet the required quality standards
• People with a medical, mental health, or social circumstance that the treating doctor judges would increase risk, affect the ability to follow the trial requirements, or make results difficult to interpret

Important: Always verify eligibility with the trial site directly before applying.